Search Results - Hans Peter Hartung

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine by Clemens Warnke, Heinz Wiendl, Hans-Peter Hartung, et al

Connect to this object online.

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis by Martin Vališ, Anat Achiron, Hans Peter Hartung, Jan Mareš, Veronika Tichá, Pavel Štourač, Simona Halusková, Francesco Angelucci, Zbyšek Pavelek

Connect to this object online.

Challenges in monitoring the quality of care in multiple sclerosis-authors' reply by Isabel Voigt, Stefanie Fischer, Undine Proschmann, Urszula Konofalska, Peggy Richter, Hannes Schlieter, Thomas Berger, Sven G. Meuth, Hans-Peter Hartung, Katja Akgün, Tjalf Ziemssen

Connect to this object online.

Consensus quality indicators for monitoring multiple sclerosis by Isabel Voigt, Stefanie Fischer, Undine Proschmann, Urszula Konofalska, Peggy Richter, Hannes Schlieter, Thomas Berger, Sven G. Meuth, Hans-Peter Hartung, Katja Akgün, Tjalf Ziemssen

Connect to this object online.

Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy by Michael A. Tortorici, Theresa Yuraszeck, David Cornblath, Vera Bril, Hans‐Peter Hartung, Gen Sobue, Richard A. Lewis, Ingemar S. J. Merkies, John‐Philip Lawo, Michaela Praus, Billie L. Durn, Orell Mielke, Xuewen Ma, Petra Jauslin, Marc Pfister, Ivo N. vanSchaik, the PATH study group

Connect to this object online.